--- title: "Summary of Xtalpi's Semi-Annual Report By GPT5" type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/33383956.md" description: "How to make big money? Choose the right stock and go all in! $XTALPI(02228.HK) Grow with it! Key performance (2025H1) Turning point in scale and profitability Revenue of RMB 517 million, up 404% YoY, achieving semi-annual profitability for the first time; Net profit of RMB 75.61 million during the period; Adjusted net profit of RMB 142 million. R&D expenses of RMB 222 million, sales/administrative expenses of RMB 40.35 million/RMB 200 million respectively. By business: Drug discovery solutions RMB 435 million (+615%), intelligent robotics solutions RMB 82 million (+96%)..." datetime: "2025-08-27T10:19:38.000Z" locales: - [en](https://longbridge.com/en/topics/33383956.md) - [zh-CN](https://longbridge.com/zh-CN/topics/33383956.md) - [zh-HK](https://longbridge.com/zh-HK/topics/33383956.md) author: "[老板的老板 AI Exec](https://longbridge.com/en/profiles/123.md)" --- # Summary of Xtalpi's Semi-Annual Report By GPT5 > How to make big money? Choose the right stock and go all in! $XTALPI(02228.HK) Grow with it! # Key Performance Highlights (2025H1) Inflection Point in Scale and Profitability Revenue of RMB 517 million, up 404% YoY, achieving semi-annual profitability for the first time; net profit of RMB 75.61 million during the period; adjusted net profit of RMB 142 million. R&D expenses were RMB 222 million, while sales/administrative expenses were RMB 40.35 million and RMB 200 million, respectively. By business: Drug Discovery Solutions contributed RMB 435 million (+615%), and Intelligent Robotics Solutions contributed RMB 82 million (+96%). By region: The U.S. accounted for RMB 413 million, while mainland China contributed RMB 79.45 million. High customer concentration: Customer A contributed RMB 365 million (\>70%). Basic earnings per share were RMB 0.0151. Core Drivers and Milestones Major collaboration with DoveTree: First-phase upfront payment of $51 million confirmed; agreement includes potential milestone payments exceeding $590 million and single-digit royalties (all contingent). Antibody business also saw significant growth, with XtalFold® launching Ultra mode and licensing to multinational pharmaceutical companies. Pipeline Progress: Three projects with leading pharmaceutical companies reached key milestones; one chronic disease project achieved PCC ahead of schedule. Collaborative PRMT5 inhibitor (PE-0260) entered IND and initiated clinical trials. The world's first AI+organoid-enabled targeted therapy for diffuse gastric cancer, developed in collaboration with "Xigen Biotechnology," received FDA ODD and Fast Track designation. Phase I, Dose Group 4 completed enrollment. Intelligent Robotics/AI Platform: Accumulated 26 million chemical reaction data points, with reaction prediction success rate \>85%; launched "Agile Spoon" to address micro-powder dispensing challenges; acquired Liverpool ChiroChem to strengthen chiral chemistry data. Commercial Expansion: Signed multi-million-dollar or strategic collaborations with JW Pharmaceutical (South Korea), Liangzhu Lab, and Roche to accelerate global deployment. New Modalities/Algorithms: Molecular Glue Platform (predicted ~1,000 CRBN targets, 1.1M virtual library with initial hits); PepiX™ Peptide Platform (\>2,000 non-natural amino acid library; milestones include AI cancer vaccines, oral metabolic products, and NCCS projects); mRNA2vec presented at AAAI, significantly reducing sequence optimization cycles. Included in the MSCI China Small Cap Index. Cash and Capital Structure Total "cash + deposits + liquid fair-value financial assets + restricted cash" stood at RMB 5.308 billion, with monthly cash burn reduced to RMB 49.7 million, supporting ~107 months (~8.9 years) at current rates. Two placements in Jan/Feb 2025 raised net proceeds of ~HKD 3.1+ billion; bank loans totaled RMB 281 million (fixed rate ≤3.2%), with ample net cash overall. Receivables surged to RMB 497 million, primarily due to DoveTree’s upfront payment (fully recovered by announcement date). # Management Outlook & Guidance (Summary) Strategic Focus: Drive paradigm shifts in drug/material R&D via "AI + Embodied Intelligence (Robotics) + High-Quality Data"; deepen model/platform collaborations with major pharma (e.g., Pfizer), advancing XFEP localization and multimodal applications. Key Business Priorities: Drug Discovery: Advance milestones for DoveTree and other major collaborations, expand antibody platform commercialization and licensing. Robotics Solutions: Deploy Multi-Agent systems across synthesis workflows, replicate across more clients/scenarios; accelerate international deliveries (JW/Liangzhu/Roche). New Modalities: Molecular Glue, PepiX™, and mRNA2vec form differentiated moats, enabling service revenue and milestone potential for in-house/joint projects. Capital Allocation: Placement funds allocated to product iteration, commercial expansion, potential M&A, and talent acquisition; no interim dividends. # Investor Focus: Three Key Themes/Risks Milestone & Revenue Volatility: DoveTree and similar large deals drive periodic revenue/receivable spikes, potentially causing quarterly fluctuations (uncertainty around subsequent $49M+ milestones). Customer Concentration: \>70% reliance on Customer A; monitor new/renewed projects for diversification. Execution & Integration: Critical factors include LCC/Shanghai SW mergers, new platform engineering, overseas delivery cadence, and compliance (esp. clinical/data). # H2 & Next 12M Trackable Metrics (Suggested) New/Progressed Collaborations: New contract value, milestone achievements, and cash collection pace. Antibody/New Modality KPIs: Licensees/collaborators, annualized recurring revenue (if disclosed), platform accuracy/update frequency. Robotics Offshore Delivery: JW/Liangzhu/Roche project acceptance and Phase II expansion. Cash Flow & Receivables: Operating cash flow improvement, DSO trends. * * * GPT says: Here’s a "conclusion-first" take: Start with performance quality, then address sustainability and realistic expectations for the next 6–12 months. # My Assessment (H1 Performance "Quality") **Volume-Price Growth + First Semi-Annual Profit**: Revenue RMB 517M (+404%), adjusted net profit RMB 142M—first semi-annual profit, marking an inflection point. **Growth Structure: Milestone-Driven + Robotics Surge**: Drug Discovery Solutions (RMB 435M, +615%) fueled by DoveTree’s $51M upfront; Robotics Solutions (RMB 81.86M, +95.9%). "Platform + Mega-Deals" is the core engine; hardware/automation scaling but still small. **Customer/Revenue Recognition: Concentrated & Volatile**: Customer A contributed RMB 365M (\>70%); "point-in-time" recognition dominated (RMB 473M of RMB 4.733B segment revenue), implying sensitivity to "large milestones." **Solid Cash Cushion, But Watch Working Capital**: RMB 5.308B "cash + equivalents" supports ~107 months (~8.9 years) at H1 burn; cash significantly exceeds loans (+RMB 5.027B). Receivables spike (RMB 497M) explained as DoveTree payment (recovered). **Costs & Investment**: R&D expenses RMB 222M, maintaining high intensity; basic EPS RMB 0.0151. # Quality Insights (My Top Three) **"Platform Validation" Moment**: DoveTree deal not just a one-off but external validation of "AI + Robotics" platform, with follow-on payments and massive milestone/royalty potential. **Structural Risks Manageable**: High concentration and "lumpy" recognition may sustain quarterly swings, but strong cash position buffers execution. **Next Operational Test**: Shift "milestone revenue" toward "recurring/periodic" and diversify client base. # Next 6–12M Expectations (Scenarios) **Base (Most Likely)**: DoveTree progresses, 1–2 more milestones triggered; robotics grows fast but remains secondary; revenue fluctuates quarterly but stays profitable. **Bull (Optimistic)**: 1–2 new "$10M+" deals/milestones; non-U.S./China regions expand. **Bear (Cautious)**: Key milestones delayed → quarterly revenue/profit dips; concentration persists; high R&D squeezes margins. # Top 5 Metrics to Watch **Milestone Execution & Cash Flow** (announcements + cash statements); **Revenue Mix**: By segment and "point vs. period" recognition; **Customer Concentration Trend** (Top1 % decline); **Receivables & Turnover** (amounts + aging/bad debt); **Robotics Offshore Delivery** (revenue/gross margin upside). # One-Sentence Verdict \*\*Two stars for "inflection" (growth + profit), but a question mark on "sustainability" (concentration + lumpy recognition).\*\* Cash and tech moat buy time to turn "validated deals" into "scalable business." Near-term: milestone pace; mid-term: client diversity + recurring revenue. ### Related Stocks - [02228.HK](https://longbridge.com/en/quote/02228.HK.md) ## Comments (19) - **花有重開日 · 2025-08-27T11:54:13.000Z · 👍 1**: Got it. Going all in with margin trading. - **江汉南京 · 2025-08-27T11:50:17.000Z**: Tomorrow will be another day of great success. - **元仔 · 2025-08-27T11:33:56.000Z · 👍 1**: It looks like we're going to have a big feast tomorrow. Let's relax and enjoy! - **泠夜辉 · 2025-08-27T11:30:15.000Z**: Boss, does this accounts receivable mean the previous $49 million hasn't been received yet? - **wolf-001** (2025-08-27T12:10:42.000Z): Already credited - **泠夜辉** (2025-08-27T12:20:34.000Z): Thank you, Mr. Li, for the explanation. Could it be the remaining $49 million down payment? - **wolf-001** (2025-08-27T12:22:44.000Z): No, this report was prepared earlier, and the payment was received later. - **嘻嘻Monica · 2025-08-27T10:35:44.000Z**: Why does it feel like everything is as expected 🥹 Will it not fall tomorrow? - **老板的老板 AI Exec** (2025-08-27T10:41:27.000Z): A dip is a buying opportunity. Don't panic. Jingtai is just taking its first step on the path of growth. We need to think about its greater future and whether it can be realized. - **海公牛** (2025-08-27T10:43:46.000Z): The company turned losses into profits with quadruple earnings. That's impressive. - **嘻嘻Monica** (2025-08-27T10:52:45.000Z): I filled my position today 🥹🥹 should wait and see tomorrow's - **心态稳定 · 2025-08-27T10:27:40.000Z**: Boss, do you have the link to the earnings conference? Couldn't find it. - **俗世文人** (2025-08-27T10:35:20.000Z): Official website - **心态稳定** (2025-08-27T11:17:10.000Z): Sorry, I really couldn't find it. Brother, could you please send it? - **俗世文人** (2025-08-27T11:32:47.000Z): https://ir.xtalpi.com/media/fvsb1es5/2025-interim-results-announcement-c.pdf - **Peterzhu202 · 2025-08-27T10:26:05.000Z**: Hard work, thank you!